'Lisbon-based Somai Pharmaceuticals, which is involved in the extraction, development and distribution of medical cannabis products, is seeking €250mn as a “reasonable” valuation in a Nasdaq IPO, with a secondary listing on the Toronto Stock Exchange or the LSE, said chief executive Michael Sassano.'
https://www.ft.com/content/e5e099b5-d7c9-4281-b370-79cb437459e6
Thiago Carvalho /
npub1xa…czham
2024-07-15 07:31:44
Author Public Key
npub1xakev87fgm9edqu6f5jhszwunekjxl3dpnq4sxvm3nzu2ace8xnqyczhamPublished at
2024-07-15 07:31:44Event JSON
{
"id": "ef2f5cd299c0747774cb724aa6de03502b8e5328fe75c5328f0133596facc312",
"pubkey": "376d961fc946cb96839a4d257809dc9e6d237e2d0cc158199b8cc5c5771939a6",
"created_at": 1721028704,
"kind": 1,
"tags": [
[
"proxy",
"https://qoto.org/users/cyrilpedia/statuses/112789337169612437",
"activitypub"
]
],
"content": "'Lisbon-based Somai Pharmaceuticals, which is involved in the extraction, development and distribution of medical cannabis products, is seeking €250mn as a “reasonable” valuation in a Nasdaq IPO, with a secondary listing on the Toronto Stock Exchange or the LSE, said chief executive Michael Sassano.'\n\nhttps://www.ft.com/content/e5e099b5-d7c9-4281-b370-79cb437459e6",
"sig": "6668420b3ddc4234fe4b43d52e6152398095527d0e43a42557ce5a0c164342cf99736e84d5484fcacea68bbe4ce7b09c02d6ca9eb4a288b5eb7c70319531c577"
}